ObsEva

ObsEva is a Swiss-based company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva´s lead product is a clinical stage compound licensed from Merck Serono.

http://www.obseva.com

Team Member
more about
Jasper Bos
Latest News Entry
2017/01/26
ObsEva SA Announces Pricing of Initial Public Offering

Geneva, Switzerland - January 25, 2017 - ObsEva SA (ObsEva) announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "OBSV" on January 26, 2017.

Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the proposed offering.

all portfolio news